Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.

Publikation

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.

Wissenschaftlicher Artikel/Review - 25.02.2022

Zeng Linan, Walsh Michael, Guyatt Gordon, Siemieniuk Reed A C, Collister David, Booth Michelle, Brown Paul, Farrar Lesha, Farrar Mark, Firth Tracy, Fussner Lynn A, Kilian Karin, Little Mark A, Mavrakanas Thomas A, Mustafa Reem A, Piram Maryam, Stamp Lisa K, Xiao Yingqi, Lytvyn Lyubov, Agoritsas Thomas, Vandvik Per O, Mahr Alfred

Zitation

Zeng L, Walsh M, Guyatt G, Siemieniuk R, Collister D, Booth M, Brown P, Farrar L, Farrar M, Firth T, Fussner L, Kilian K, Little M, Mavrakanas T, Mustafa R, Piram M, Stamp L, Xiao Y, Lytvyn L, Agoritsas T, Vandvik P, Mahr A. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ 2022; 376:e064597.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMJ 2022; 376

Veröffentlichungsdatum

25.02.2022

eISSN (Online)

1756-1833

Seiten

e064597

Kurzbeschreibung/Zielsetzung

What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial.